The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Livalo     calcium(3R,5S)-7-[2- cyclopropyl-4-(4...

Synonyms:
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Livalo

 

High impact information on Livalo

 

Chemical compound and disease context of Livalo

 

Biological context of Livalo

 

Anatomical context of Livalo

  • NK-104 showed marked inhibition in liver (ED50 0.13 mg/kg) and in ileum (ED50 0.20 mg/kg), but much weaker in the other tissues [12].
  • Liver endoplasmic reticulum (ER) was isolated and measured for lipid content and activity of ER enzymes (NK-104: 3 mg/kg, SV: 30 mg/kg) [13].
  • NK-104 decreased the surface lesion area at the arch (23.1%, p = 0.054) and reduced the degeneration of media in the thoracic aorta (69.9% increase in medial smooth muscle cells, p < 0.01) [14].
  • There was no inhibitory effect of NK-104 on CYP-mediated metabolism of taxol in human liver microsomes [15].
 

Associations of Livalo with other chemical compounds

 

Gene context of Livalo

 

Analytical, diagnostic and therapeutic context of Livalo

  • The proposed method has been applied to plasma samples obtained after oral administration of a single 2 mg dose of NK-104 to volunteers [10].
  • Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection [10].
  • A simple and sensitive column-switching HPLC method has been developed for the simultaneous determination of NK-104 (HMG-CoA reductase inhibitor) and its lactone in human and dog plasma [10].
  • Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay--inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase [15].

References

  1. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Ooyen, C., Zecca, A., Bersino, A.M., Catapano, A.L. Atherosclerosis (1999) [Pubmed]
  2. Six-month repeated oral toxicity study of NK-104 in rats. Akiba, T., Shibuta, T., Amano, Y., Asanuma, A., Okubo, M., Nishigaki, K., Moriwaki, T., Yamada, H., Okamura, N., Watanabe, T., Koga, T., Tanaka, M., Takimoto, M. The Journal of toxicological sciences. (1998) [Pubmed]
  3. NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. Takemoto, M., Kitahara, M., Yokote, K., Asaumi, S., Take, A., Saito, Y., Mori, S. Br. J. Pharmacol. (2001) [Pubmed]
  4. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Suzuki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. Atherosclerosis (1999) [Pubmed]
  5. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Kibayashi, E., Urakaze, M., Kobashi, C., Kishida, M., Takata, M., Sato, A., Yamazaki, K., Kobayashi, M. Clin. Sci. (2005) [Pubmed]
  6. Effect of NK-104, a new synthetic HMG-CoA reductase inhibitor, on triglyceride secretion and fatty acid oxidation in rat liver. Yamamoto, K., Todaka, N., Goto, H., Jayasooriya, A.P., Sakono, M., Ogawa, Y., Fukuda, N. Life Sci. (1999) [Pubmed]
  7. 28-day repeated oral toxicity study of a hypolipidemic agent, NK-104 in rats. Akiba, T., Shibuta, T., Amano, Y., Okubo, M., Asanuma, A., Koga, T., Tanaka, M., Takimoto, M. The Journal of toxicological sciences. (1998) [Pubmed]
  8. NK-104, a newly developed HMG-CoA reductase inhibitor, suppresses neointimal thickening by inhibiting smooth muscle cell growth and fibronectin production in balloon-injured rabbit carotid artery. Kitahara, M., Kanaki, T., Toyoda, K., Miyakoshi, C., Tanaka, S., Tamaki, T., Saito, Y. Jpn. J. Pharmacol. (1998) [Pubmed]
  9. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Kojima, J., Fujino, H., Abe, H., Yosimura, M., Kanda, H., Kimata, H. Biol. Pharm. Bull. (1999) [Pubmed]
  10. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Kojima, J., Fujino, H., Yosimura, M., Morikawa, H., Kimata, H. J. Chromatogr. B Biomed. Sci. Appl. (1999) [Pubmed]
  11. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. Morikawa, S., Umetani, M., Nakagawa, S., Yamazaki, H., Suganami, H., Inoue, K., Kitahara, M., Hamakubo, T., Kodama, T., Saito, Y. J. Atheroscler. Thromb. (2000) [Pubmed]
  12. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Aoki, T., Nishimura, H., Nakagawa, S., Kojima, J., Suzuki, H., Tamaki, T., Wada, Y., Yokoo, N., Sato, F., Kimata, H., Kitahara, M., Toyoda, K., Sakashita, M., Saito, Y. Arzneimittel-Forschung. (1997) [Pubmed]
  13. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Suzuki, H., Yamazaki, H., Aoki, T., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. Arzneimittel-Forschung. (2001) [Pubmed]
  14. Lipid-lowering and antiatherosclerotic effect of NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits. Suzuki, H., Yamazaki, H., Aoki, T., Kojima, J., Tamaki, T., Sato, F., Kitahara, M., Saito, Y. Arzneimittel-Forschung. (2000) [Pubmed]
  15. Simultaneous determination of taxol and its metabolites in microsomal samples by a simple thin-layer chromatography radioactivity assay--inhibitory effect of NK-104, a new inhibitor of HMG-CoA reductase. Fujino, H., Yamada, I., Shimada, S., Yoneda, M. J. Chromatogr. B Biomed. Sci. Appl. (2001) [Pubmed]
  16. Novel statins: pharmacological and clinical results. Bolego, C., Poli, A., Cignarella, A., Catapano, A.L., Paoletti, R. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. (2002) [Pubmed]
  17. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. Fujino, H., Yamada, I., Shimada, S., Nagao, T., Yoneda, M. Arzneimittel-Forschung. (2002) [Pubmed]
  18. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Han, J., Parsons, M., Zhou, X., Nicholson, A.C., Gotto, A.M., Hajjar, D.P. Circulation (2004) [Pubmed]
  19. Studies on the interaction between fibrates and statins using human hepatic microsomes. Fujino, H., Shimada, S., Yamada, I., Hirano, M., Tsunenari, Y., Kojima, J. Arzneimittel-Forschung. (2003) [Pubmed]
 
WikiGenes - Universities